Antiplatelet therapy for Staphylococcus aureus bacteremia: Will it stick?

Area of Science:

• Infectious Diseases
• Pharmacology
• Immunology

Background:

• Staphylococcus aureus bacteremia (SAB) is a significant clinical challenge.
• Repurposing existing drugs like ticagrelor offers a promising strategy due to established safety profiles.
• Ticagrelor, an antiplatelet agent for acute coronary syndrome (ACS), shows potential in mitigating SAB severity.

Purpose of the Study:

• To review clinical data on ticagrelor's impact on S. aureus infections.
• To explore proposed mechanisms of action for ticagrelor against S. aureus.
• To assess the potential of ticagrelor as an adjunctive therapy for SAB.

Main Methods:

• Review of existing clinical data and observational studies.
• Exploration of in vitro and preclinical evidence for proposed mechanisms.
• Synthesis of information on ticagrelor's pharmacological effects and S. aureus virulence.

Main Results:

• Clinical data suggest a correlation between ticagrelor use and improved outcomes in SAB patients.
• Potential mechanisms include direct antibacterial effects, enhanced platelet-mediated bacterial killing, and reduced bacterial adhesion.
• Ticagrelor's antiplatelet action may influence host-pathogen interactions.

Conclusions:

• Ticagrelor exhibits potential as a therapeutic agent against S. aureus infections.
• Further investigation is warranted to validate these findings and establish clinical guidelines.
• Targeting the host-pathogen interface with repurposed drugs like ticagrelor is a promising research avenue.